Ticker Details
Summit Therapeutics Inc. Common Stock Summit Therapeutics PLC is a biopharmaceutical company focused on the discovery, development and commercialization of novel medicines for indications for which there are no existing or only inadequate therapies.
IPO Date:	April 1, 2015
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$12.01B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.32 | 4.17%
Avg Daily Range (30 D):	$0.41 | 2.60%
Avg Daily Range (90 D):	$0.61 | 3.40%

Institutional Daily Volume
Avg Daily Volume:	1.14M
Avg Daily Volume (30 D):	5.53M
Avg Daily Volume (90 D):	4M

Trade Size
Avg Trade Size (Sh.):	133
Avg Trade Size (Sh.) (30 D):	106
Avg Trade Size (Sh.) (90 D):	92

Institutional Trades
Total Institutional Trades:	1,784
Avg Institutional Trade:	$3.16M
Avg Institutional Trade (30 D):	$3.17M
Avg Institutional Trade (90 D):	$2.98M
Avg Institutional Trade Volume:	.2M
Avg Institutional Trades (Per Day):	2

Market Closing Trades
Avg Closing Trade:	$5.83M
Avg Closing Trade (30 D):	$10.32M
Avg Closing Trade (90 D):	$7.86M
Avg Closing Volume:	391.02K

News

Jun 10, 2026 @ 5:13 PM Oil Jumps On Iran Strikes, Nasdaq 100 Falls On Hot... Source: Piero Cingari

May 23, 2026 @ 10:13 PM Why a Biotech Fund Opened a New $6 Million Positio... Source: Jonathan Ponciano

May 3, 2026 @ 1:16 PM Roblox, Spotify, And Robinhood Are Among Top 10 La... Source: Nabaparna Bhattacharya

May 1, 2026 @ 5:11 PM Stock Market Today: Apple Earnings Power S&P 500, ... Source: Piero Cingari

Apr 19, 2026 @ 2:01 PM IonQ, Oklo, And Robinhood Are Among the Top 10 Lar... Source: Nabaparna Bhattacharya

Financials
	TTM	Q4 2025	FY 2025
Basic EPS	$-1.44	$-.28	$-1.44
Diluted EPS	$-1.44	$-.28	$-1.44
Revenue
Gross Profit
Net Income / Loss	$-1079.59M	$-219.17M	$-1079.59M
Operating Income / Loss
Cost of Revenue
Net Cash Flow	$120.29M	$-13.27M	$120.29M
PE Ratio